Vertex Pharma (VRTX) Tops Q1 EPS by 2c; Reaffirms

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. META
4. NFLX
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. USO

Go back to Vertex Pharma (VRTX) Tops Q1 EPS by 2c; Reaffirms

Vertex Reports First Quarter 2023 Financial Results

May 1, 2023 4:01 PM EDT

Product revenue of $2.37 billion, a 13% increase compared to Q1 2022

Company reiterates full year 2023 financial guidance, including product revenue guidance of $9.55 to $9.7 billion

TRIKAFTA approved in U.S. for children with cystic fibrosis 2 to 5 years of age

Pipeline advancement continues with completion of rolling BLA submissions for exa-cel in the U.S.; multiple additional clinical milestones expected in 2023

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2023 and reiterated full year... More